PolyPid Ltd.

Greetings and welcome to the PolyPEAT first quarter 2022 conference call. At this time, participants are in listen-only mode. As a reminder, this call is recorded, and I would now like to introduce your host for today's conference, Bob Jedid from LifeSci Advisors. Mr. Jedid, you may begin.

Thank you all for participating in PolyPEAT's first quarter 2022 conference call. Joining me on the call today will be Amir Weisberg, Chief Executive Officer, Tikla Chachkas-Oxobrod, Executive Vice President and Chief Financial Officer of PolyPede, and Ford Wachowski, the Chief Operating Officer for PolyPede's U.S. operation. Earlier today, the company released financial results for the three months ended March 31, 2022. A copy of the press release is available in the Investors section of the company's website, www.polypede.com. I'd like to remind you that on this call, management will make forward-looking statements within the meeting of the federal securities laws. For example, management is making forward-looking statements when it discusses the conditions for the drawdown of the second and third tranches of the Creo's capital loan, how the loan agreement broadens the company's financing options and provides it with access on a non-dilutive basis to significant additional capital, the company's pipeline, the expected benefits from recent executive appointments, the expected timing and recruitment for trials, the interim data analysis, the expected timing, the release of its results, and the potential implications. In addition, forward-looking statements include future commercialization of the company's products, potential use and benefits of DPLEX-100 and OncoPlex, market opportunity for Dplex 100, the U.S. addressable market for Dplex 100, its ongoing pre-commercialization preparations and pre-launch activities, the company's potential partners, additional publications and presentations at important scientific conferences, and sufficiency of the company's cash to fund future operations into the second quarter of 2023. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks described from time to time in our SEC filings. Our results may differ materially from those projections. These statements involve material risks and uncertainties that could cause actual results or events to materially differ. Accordingly, you should not place undue reliance on these statements. I encourage you to review the company's filings with the SEC including without limitation the company's form 20F, which identifies specific factors which may cause actual results or events to differ materially from those described in the forward-looking statements. PolyP describes, disclaims any intention or obligation that is required by law to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information. It speaks only as of the live broadcast today, May 11th, 2022. A copy of the slides the management team will review on this call can be found on the investor section of the company's website at investors.pallyp.com. With completion of those prepared remarks, it's my pleasure to turn the call over to Amir Weisberg, CEO. Amir.

Thank you, Bob. On behalf of our team at PolyPID, I would like to welcome everyone to our first quarter 2022 earnings call. As this will be my final earnings conference call as a CEO, I would like to take this opportunity to thank the board and our shareholder for their support and confidence in allowing me to serve as a CEO of PolyPID for over 11 years. I am also grateful to all of my colleagues at PolyPID for their hard work and commitment during this development stage, which allow us to accomplish much over the years. PolyPID is now a position of strength clinically, operationally, and financially. As we advance with our phase three trial, and there are Near potential commercialization, it is current time for Dikla to lead the company into its next phase of growth. Therefore, once again, I would like to congratulate Dikla on her well-deserved appointment as a CEO, which will become effective July 1st. Since joining Polypid seven years ago, Dikla has been key guiding the company towards our objectives. As a shareholder, along with our other shareholders on this call, I look forward to the DMC recommendation on our SHIELD-1 trial once the interim data on 750 patients is fully analyzed and to the continued development of our promising pipeline product candidate OncoPlex for the treatment of solid tumors. With that, I will now turn the call over to Dikla to provide a detailed update, including a discussion of upcoming key milestones and review of our financial results. Following this, she will open the call for your question. Dikla?